Your browser doesn't support javascript.
loading
Porocarcinomas with PAK1/2/3 fusions: a series of 12 cases.
Kervarrec, Thibault; Westphal, Danna; Pissaloux, Daniel; Legrand, Mélanie; Tirode, Franck; Neuhart, Anne; Drouot, Francoise; Becker, Jürgen C; Macagno, Nicolas; Seris, Alice; Jouary, Thomas; Beltzung, Fanny; Jullie, Marie-Laure; Harms, Paul W; Cribier, Bernard; Mourah, Samia; Jouenne, Fanélie; Fromont, Gaelle; Louveau, Baptiste; Mancini, Maxence; Kazakov, Dmitry V; de la Fouchardière, Arnaud; Battistella, Maxime.
Affiliation
  • Kervarrec T; Department of Pathology, Centre Hospitalier Universitaire de Tours, Université de Tours, Tours, France.
  • Westphal D; "Biologie des infections à polyomavirus" Team, UMR INRA ISP 1282, Université de Tours, Tours, France.
  • Pissaloux D; CARADERM Network.
  • Legrand M; National Center for Tumour Diseases (NCT), Partner Site Dresden, Dresden, Germany.
  • Tirode F; Department of Dermatology, University Hospital Carl Gustav Carus, Dresden, Germany.
  • Neuhart A; Department of Biopathology, Center Léon Bérard, Lyon, France.
  • Drouot F; Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Equipe Labellisée Ligue contre le Cancer, Lyon, France.
  • Becker JC; Department of Pathology, Centre Hospitalier Universitaire de Tours, Université de Tours, Tours, France.
  • Macagno N; Department of Biopathology, Center Léon Bérard, Lyon, France.
  • Seris A; Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Equipe Labellisée Ligue contre le Cancer, Lyon, France.
  • Jouary T; Department of Biopathology, Center Léon Bérard, Lyon, France.
  • Beltzung F; Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Equipe Labellisée Ligue contre le Cancer, Lyon, France.
  • Jullie ML; CARADERM Network.
  • Harms PW; Department of Pathology, Cypath, Dijon, France.
  • Cribier B; Department of Translational Skin Cancer Research, University Hospital Essen, Essen, Germany.
  • Mourah S; Department of Dermatology, University Hospital Essen, Essen, Germany.
  • Jouenne F; German Cancer Consortium (DKTK), Pa German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Fromont G; CARADERM Network.
  • Louveau B; Department of Pathology, Timone University Hospital, Marseille, France.
  • Mancini M; CARADERM Network.
  • Kazakov DV; Service de Dermatologie, Centre hospitalier de Pau, Pau, France.
  • de la Fouchardière A; CARADERM Network.
  • Battistella M; Service de Dermatologie, Centre hospitalier de Pau, Pau, France.
Histopathology ; 2024 May 24.
Article in En | MEDLINE | ID: mdl-38785043
ABSTRACT

AIMS:

Porocarcinoma is a malignant sweat gland tumour differentiated toward the upper part of the sweat duct and may arise from the transformation of a preexisting benign poroma. In 2019, Sekine et al. demonstrated the presence of YAP1MAML2 and YAP1NUTM1 fusions in most poromas and porocarcinomas. Recently, our group identified PAK2-fusions in a subset of benign poromas. Herein we report a series of 12 porocarcinoma cases harbouring PAK1/2/3 fusions. METHODS AND

RESULTS:

Five patients were male and the median age was 79 years (ranges 59-95). Tumours were located on the trunk (n = 7), on the thigh (n = 3), neck (n = 1), or groin area (n = 1). Four patients developed distant metastases. Microscopically, seven cases harboured a benign poroma component and a malignant invasive part. Ductal formations were observed in all, while infundibular/horn cysts and cells with vacuolated cytoplasm were detected in seven and six tumours, respectively. In three cases, the invasive component consisted of a proliferation of elongated cells, some of which formed pseudovascular spaces, whereas the others harboured a predominant solid or trabecular growth pattern. Immunohistochemical staining for CEA and EMA confirmed the presence of ducts. Focal androgen receptor expression was detected in three specimens. Whole RNA sequencing evidenced LAMTOR1PAK1 (n = 2), ZDHHC5PAK1 (n = 2), DLG1PAK2, CTDSP1PAK1, CTNND1PAK1, SSR1PAK3, CTNNA1PAK2, RNF13PAK2, ROBO1PAK2, and CD47PAK2. Activating mutation of HRAS (G13V, n = 3, G13R, n = 1, Q61L, n = 2) was present in six cases.

CONCLUSION:

Our study suggests that PAK1/2/3 fusions is the oncogenic driver of a subset of porocarcinomas lacking YAP1 rearrangement.

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Histopathology Year: 2024 Type: Article Affiliation country: France

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Histopathology Year: 2024 Type: Article Affiliation country: France